Shimadzu is developing global approaches throughout marketing, development, production, sales and service to become a better, more reliable partner to worldwide customers. We conducted an interview with Bayer Schering Pharma, a major pharmaceutical company in Germany that uses Shimadzu’s MCE®-202 microchip electrophoresis system for DNA/RNA analysis. The interview was set up through Shimadzu’s European regional headquarters (Shimadzu Europa GmbH) and its sales subsidiary (Shimadzu Deutschland GmbH).
Bayer Schering Pharma,
Tumor Cell Research
Please introduce your study and your role in your lab.
What are you using MultiNA for? How many people in your lab are using MultiNA? How often?
Why did you choose MultiNA?
(*) In this context, "safer" referred to the fact that it is not necessary to use ethidium bromide as a fluorescent material adhesive of agarose gel.
What are the advantages and benefits of MultiNA? Please let us know your impression and opinion after the actual installation of MultiNA.
Please let us know any ideas about improving and enhancing MultiNA.
Please let us know your requests for Shimadzu technology, products and service
Thank you for your time.
MCE®-202 MultiNA Development Story
The development of MultiNA has been achieved by combining various technologies, such as automatic injection and quartz microchip, which we have been continuously cultivating. We have also strived to improve functionality in the software for greater ease of use.
About Shimadzu Europa GmbH
Note) MultiNA is not available for sales in the United States.